Ferring Pharmaceuticals’s fecal microbiota transplant for recurrent Clostridioides difficile infection received a favorable US Food and Drug Administration advisory committee review on 22 September thanks in large part to agency advisers’ preference for more quality control and standardization in a space that has been dominated by unapproved products due to FDA enforcement discretion.
The desire for a regulated product trumped acknowledged gaps in the data package submitted for approval for most Vaccine and...





